BIGTINCAN HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.155 AUD | +3.33% |
|
+3.33% | -22.50% |
| Apr. 11 | Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19% | MT |
| Mar. 18 | Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index | CI |
Presenter SpeechJane Morgan (Attendees)So good morning. My name is Jane Morgan, and thank you ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.15
AUD
Average target price
0.39
AUD
Spread / Average Target
+160.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.50% | 61.78M | |
| +29.29% | 49.46B | |
| +0.58% | 42.58B | |
| +48.77% | 42.49B | |
| -5.26% | 29.09B | |
| +12.30% | 26.61B | |
| -24.27% | 18.64B | |
| +6.87% | 13.16B | |
| +31.96% | 12.55B | |
| +23.99% | 12.1B |
- Stock Market
- Equities
- BTH Stock
- News Bigtincan Holdings Limited
- Transcript : Bigtincan Holdings Limited - Shareholder/Analyst Call
